Robert R.
- Country
- Germany
- Department
- Klinik für Hämatologie, Onkologie und Palliativmedizin
Research Overview
- Phase III Randomized Study of Volrustomig with Carboplatin and Pemetrexed Versus Standard Care in Unresectable Pleural Mesothelioma
- Phase III Randomized Trial of Decitabine, Venetoclax, and Tretinoin in Acute Myeloid Leukemia Patients Ineligible for Induction Chemotherapy
- Phase 3 Randomized Study of Adjuvant mRNA-4157 and Pembrolizumab Versus Placebo and Pembrolizumab in Resected Stage II-IIIB Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 33 of 185 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in acute myeloid leukemia (AML) treatment approaches, with particular focus on developing innovative therapeutic strategies for patients who cannot receive standard induction chemotherapy. Their research encompasses novel combination therapies including decitabine and venetoclax with retinoid compounds.
- Newly diagnosed AML management
- Alternative treatment strategies for chemotherapy-ineligible patients
- Combination therapy approaches
Their work extends to studying genetic risk stratification in AML and developing targeted treatments for specific genetic profiles.
Advanced Therapeutics
The investigator focuses on evaluating intensive chemotherapy approaches in hematologic malignancies, including the assessment of novel formulations like CPX-351. Their research particularly addresses AML with myelodysplasia-related changes and therapy-related conditions.
- Genetic risk-adapted therapy
- Novel chemotherapy formulations
- Treatment strategies for high-risk disease
Their expertise includes managing adverse-risk genetics in hematologic disorders and developing targeted therapeutic approaches.
Thoracic Oncology
This investigator conducts research in pleural mesothelioma treatment, evaluating novel therapeutic combinations including immunotherapy approaches. Their work focuses on unresectable disease and comparing different treatment modalities.
- Advanced mesothelioma management
- Combination therapy strategies
- Novel therapeutic agents
Their research encompasses both targeted therapy and conventional chemotherapy approaches in thoracic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.